Fertility Drugs are drugs which are considered to be the primary treatment for treating the infertility in men and women. These drugs enhance the reproductive ability by improving the quality of egg or sperms by enhancing the levels of certain hormones in human body. Fertility drugs regulate the ovulation. These drugs generally work like the natural hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to trigger ovulation. They are also used in women who ovulate for trying to stimulate a better egg or extra egg/eggs. These drugs may include Gonadotropins, Clomiphene citrate, Metformin etc. Apart from this, fertility drugs carry some risks such as Pregnancy with multiples, ovarian hyperstimulation syndrome (OHSS), and Long-term risks of ovarian tumors.
According to study, “Fertility Drugs Market Global Report 2020-30” the key companies operating in the global fertility drugs market are Berlex Laboratories, Inc., Merck & Co. Pharmaceutical Company, Eli Lilly, Noven Pharmaceuticalorganon, Inc., Baxter Healthcare Corporation, Personal Products Company, Ferring Pharmaceauticals, Inc., Pfizer, Inc., Janssen Pharmaceuticals Inc., Ther-Rx Corporation, Leadiant Biosciences Inc., Procter & Gamble Pharmaceuticals, Solvay Pharmaceuticals, Inc., Emd Serono, Inc., Bayer Healthcare Pharmaceuticals, Actavis Generics, Roche Pharmaceutical, Takeda Pharmaceautical Co. Ltd. and Emd Serono Inc. The key companies are focusing on the product innovations, expansions, Mergers & Acquisition (M&A), finding new market in their core competency in order to increase individual market share.
Based on gender type, fertility drugs market is segmented as male fertility treatment and female fertility treatment. Based on treatment type, market is segmented as Intra Cytoplasmic Sperm Injection (ICSI), In Vitro Fertilization (IVF), Hormonal, Alternative & Complementry Treatment and Intra Uterine Insemination (IUI). Based on infertility type, market is segmented as unexplained infertility, endometriosis, blocked or damaged tubes, polycystic ovarian syndrome, and others. Based on route of administration, market is segmented as intravenous, oral, intramuscular and subcutaneous. Based on type of drug, market is segmented as over-the-counter drugs and prescription fertility drugs. In addition, based on distribution channel, market is segmented as retail pharmacies, hospital pharmacies and online pharmacies.
The fertility drugs market is driven by rise in prevalence of polycystic ovarian syndrome among younger women, followed by increase in average age of conceiving in women, change in lifestyle & cultural shift, increase in infertility rate among adults, surge in investment by pharma companies in fertility treatment centers, increase in sexually transmitted diseases among men & women and increase in government policies & schemes for infertility treatment. However, side-effects associated with fertility drugs such as birth defect, high cost of fertility drugs, black market of fertility drugs and high failure rate of treatment may impact the market. Moreover, growth in technological advancement, increase in awareness among people and growth in medical tourism are key opportunities for market.
Based on geography, the North-American region holds major share in global fertility drugs market owing to rise in prevalence of sedentary lifestyles & obesity in the Americas, particularly in the U.S. The Asian-Pacific and European regions are estimated to witness higher growth rate due to increase in awareness about women’s health & fertility treatments over the forecast period. The global fertility drugs market was valued at US $4.26 billion in 2019 and it is likely to grow at a CAGR of 5.80% and reach US $5.33 billion by 2023.
For More Information, Click on the Link Below:-
Ankur Gupta, Head Marketing & Communications